Achieve Life Sciences (ACHV) Expected to Announce Quarterly Earnings on Thursday

Achieve Life Sciences (NASDAQ:ACHV) will likely be releasing its earnings data before the market opens on Thursday, March 27th. Analysts expect Achieve Life Sciences to post earnings of ($0.29) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Achieve Life Sciences (NASDAQ:ACHV) last announced its quarterly earnings data on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.06). On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Achieve Life Sciences Stock Down 4.0 %

Shares of NASDAQ:ACHV opened at $2.67 on Thursday. The company has a market capitalization of $92.61 million, a price-to-earnings ratio of -2.36 and a beta of 1.67. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.78 and a quick ratio of 6.78. The business’s 50-day moving average is $3.12 and its 200-day moving average is $3.97. Achieve Life Sciences has a 1 year low of $2.51 and a 1 year high of $5.59.

Insider Buying and Selling

In other news, CFO Mark K. Oki purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average cost of $2.89 per share, with a total value of $28,900.00. Following the purchase, the chief financial officer now owns 10,000 shares in the company, valued at $28,900. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.00% of the stock is owned by company insiders.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.